Global IVD Companies Report First Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 9 – July 1, 2024 Issue

IN THEIR INITIAL FINANCIAL REPORTING F…

Read More

---

Q3 2023 Financial Reports Show Growth at Labcorp, Quest

By Robert Michel | From the Volume XXX, Number 16 – November 13, 2023 Issue

Blood brothers Labcorp and Quest Diagnostics showed momentum beyond COVID-19 testing and toward areas that grew base business revenue in their third quarter (Q3) 2023 financial reporting. Company leaders called attention to more partnerships and acquisitions of ho…

Read More

---

Labcorp: Ascension Deal Will Earn $550 Million in 2023

By Robert Michel | From the Volume XXX No. 4 – March 6, 2023 Issue

PUBLICLY TRADED LABORATORY COMPANIES OFFERED INSIGHTS into how acquisitions of hospital lab operations and outreach businesses add to their bottom lines, according to recent reports on full-year 2022 and fourth quarter earnings.  Last year was a busy one…

Read More

---

PGx Testing Labs Concerned by FDA’s Statements, Actions

By Mary Van Doren | From the Volume XXVI No. 12 – September 3, 2019 Issue

This is a synopsis of two in-depth articles in the Sept. 3, 2019 issue of THE DARK REPORT (TDR). The full articles are available to members of The Dark Intelligence Group. CEO SUMMARY: Since April, 2019, the federal Food and Drug Administration (FDA) ha…

Read More

---

What Comes Next for the Pathology Profession?

By R. Lewis Dark | From the Volume XXVI No. 12 – September 3, 2019 Issue

IT MAY NOT BE A COINCIDENCE THAT MANY RECENT NEWS CYCLES have more negative pathology news than positive pathology news. After all, laboratory medicine is at the core of most clinical care delivered to patients, so it’s no coincidence that pathology—both clinical and anatomic—is a prime target…

Read More

---

PGx Labs Concerned by FDA’s Statements, Actions

By Joseph Burns | From the Volume XXVI No. 12 – September 3, 2019 Issue

CEO SUMMARY: Since April, the federal Food and Drug Administration has taken steps that target clinical laboratories that perform pharmacogenetic (PGx) tests. In response to letters from the FDA, some PGx lab companies have stopped reporting data that predicts a patient’s response to ce…

Read More

---

Several Big Surprises in 2018’s Top 10 Lab Stories

By Robert Michel | From the Volume XXV No. 18 – December 24, 2018 Issue

CEO SUMMARY: This year’s list of the Top 10 Lab Industry Stories for 2018 is dominated by new directives from Medicare and private health insurers, as well as significant decisions by federal courts. Collectively, these developments create new compliance risks for all clinical laborator…

Read More

---

Key Lab Trends Described At Executive War College

By Joseph Burns | From the Volume XXV No. 7 – May 7, 2018 Issue

CEO SUMMARY: Innovative clinical labs and pathology groups are absorbing this year’s Medicare Part B price cuts while continuing to pursue opportunities to add value. A common theme from many speakers at last week’s Executive War College in New Orleans is that the lab must get mastery…

Read More

---

A coming transformation: Control over important diagnostic technologies is about to change hands

By Mary Van Doren | From the Volume XXV No. 5 – March 26, 2018 Issue

This is an excerpt from a 2,920-word article in the March 26, 2018, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group. CEO SUMMARY: He…

Read More

---

Why Pharma, Private Equity Want to Reshape Lab Industry

By Joseph Burns | From the Volume XXV No. 5 – March 26, 2018 Issue

CEO SUMMARY: A disruptive force that involves precision medicine, pharmaceutical companies, and venture capital investors is poised to reshape the clinical laboratory industry. Genetic knowledge makes it possible to match cancer drugs to specific mutations. Pharma companies and professio…

Read More

---